20-332 - GOG-3039 - A Phase II Study of Abemaciclib in Combination with Letrozole in Advanced, Recurrent or Metastatic Endometrioid Endometrial CancerStatus: open
Abemaciclib and Letrozole to Treat Endometrial Cancer
Patients with Endometrial Carcinoma
This is a phase II single arm trial to evaluate the objective response rate of abemaciclib and letrozole in advanced stage, persistent or recurrent endometrioid endometrial cancer. Treatment will continue until either unacceptable toxicity, progression of disease, or investigator/patient request for withdrawal.
SponsorsThis trial is sponsored by National Cancer Institute (NCI).
Providers Associated With This Trial
- Jennifer M. Scalici, M.D.Gynecologic OncologistChief of Gynecologic Oncology Service; Professor of Interdisciplinary Clinical Oncology
- Jennifer Young Pierce, M.D., M.P.H., F.A.C.O.G.Gynecologic OncologistLeader of Cancer Control and Prevention; Program Director for the Gynecologic Oncology Fellowship; Professor of Interdisciplinary Clinical Oncology
- Nathaniel Jones, M.D.Gynecologic OncologistAssistant Professor of Interdisciplinary Clinical Oncology